# Study of Efficacy of Ranibizumab in Different Regimens in Patients With Diabetic Macula Edema

> **NCT02366468** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 135 (actual)

## Conditions studied

- Diabetic Retinopathy

## Interventions

- **DRUG:** ranibizumab 0.5 mg

## Key facts

- **NCT ID:** NCT02366468
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-23
- **Primary completion:** 2017-06-08
- **Final completion:** 2017-06-08
- **Target enrollment:** 135 (ACTUAL)
- **Last updated:** 2019-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02366468

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02366468, "Study of Efficacy of Ranibizumab in Different Regimens in Patients With Diabetic Macula Edema". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02366468. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*